Table of Contents

company-logo

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on biologic therapies for autoimmune and allergic diseases in the People's Republic of China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor for the treatment of ankylosing spondylitis (AS) and lupus nephritis (LN); and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra to treat atopic dermatitis (AD), prurigo nodularis (PN), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU), asthma, and chronic obstructive pulmonary disease (COPD). The company also develops QX001S, an IL-12/IL-23p40 inhibitor for the treatment of psoriasis (Ps) and ulcerative colitis (UC)/Crohn's disease (CD); QX004N an IL-23p19 inhibitor to treat Ps and CD; QX006N, an IFNAR1-targeting mAb for the treatment of systemic lupus erythematosus (SLE); and QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin designed to treat moderate-to-severe asthma and COPD. In addition, it develops QX007N targeting IL-33 for the treatment of COPD and asthma; QX013N, a humanized IgG1 mAb targeting c-kit to treat CSU; and QX010N, an IL-31R inhibitor for the treatment of pruritus. The company engages in the research, development, and production of pharmaceutical products; and provision of technical consultation services. Qyuns Therapeutics Co., Ltd. was founded in 2015 and is headquartered in Taizhou, China.

Qyuns Therapeutics Co Dividend Announcement

• Qyuns Therapeutics Co does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Qyuns Therapeutics Co dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Qyuns Therapeutics Co Dividend History

Qyuns Therapeutics Co Dividend Yield

Qyuns Therapeutics Co current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Qyuns Therapeutics Co stock? Use our calculator to estimate your expected dividend yield:

Qyuns Therapeutics Co Financial Ratios

P/E ratio-5.14
PEG ratio-0.06
P/B ratio6.05
ROE-118.82%
Payout ratio0.00%
Current ratio1.86
Quick ratio1.83
Cash Ratio1.28

Qyuns Therapeutics Co Dividend FAQ

Does Qyuns Therapeutics Co stock pay dividends?
Qyuns Therapeutics Co does not currently pay dividends to its shareholders.
Has Qyuns Therapeutics Co ever paid a dividend?
No, Qyuns Therapeutics Co has no a history of paying dividends to its shareholders. Qyuns Therapeutics Co is not known for its dividend payments.
Why doesn't Qyuns Therapeutics Co pay dividends?
There are several potential reasons why Qyuns Therapeutics Co would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Qyuns Therapeutics Co ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Qyuns Therapeutics Co has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Qyuns Therapeutics Co a dividend aristocrat?
Qyuns Therapeutics Co is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Qyuns Therapeutics Co a dividend king?
Qyuns Therapeutics Co is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Qyuns Therapeutics Co a dividend stock?
No, Qyuns Therapeutics Co is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Qyuns Therapeutics Co stocks?
To buy Qyuns Therapeutics Co you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Qyuns Therapeutics Co stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.